P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)
Paul G. Richardson,Angela R. Smith,Nancy A. Kernan,Joseph H. Antin,Leslie Lehmann,Robert J. Ryan,Robin Hume,William Tappe,Stephan A. Grupp +8 more
TL;DR: In this article, a pooled analysis compared overall survival among groups based on severity of VOD/SOS, including those with MOD and those who were ventilator- or dialysis-dependent.
Journal ArticleDOI
Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site
Eric R. Goedken,Maria A. Argiriadi,Justin Dietrich,Andrew M. Petros,Nava Krishnan,Sanjay C. Panchal,Wei Qiu,Haihong Wu,Haizhong Zhu,Ashley M Adams,Pierre Bodelle,Lucas Goguen,Paul G. Richardson,Peter F. Slivka,Myron Srikumaran,Anup K. Upadhyay,Bainan Wu,Russell A. Judge,Anil Vasudevan,Sujatha M. Gopalakrishnan,Philip B. Cox,Vincent Sol,Chaohong Sun +22 more
TL;DR: In this article , the authors used an NMR-based fragment screen of recombinant IL17A to uncover starting points for small molecule anti-IL17A antagonist discovery and obtained compounds with increased binding affinity.
Journal ArticleDOI
Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.
Melissa G. Ooi,Paul Dowling,Paul G. Richardson,Constantine S. Mitsiades,Martin Clynes,Kenneth C. Anderson,Peter O'Gorman +6 more
TL;DR: Resistance mechanism after bortezomib treatment is examined by using paired sensitive and resistant cell lines and 18 proteins have been identified to be differentially expressed in the sensitive cell line compared to theresistant cell lines.
Journal ArticleDOI
Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma
Gullu Gorgun,Teru Hideshima,Naoya Mimura,Diana Cirstea,Loredana Santo,Yiguo Hu,Claire Fabre,Noopur Raje,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +10 more
TL;DR: The data suggest that HDAC 6 may have an immune regulatory function, and that inhibition of HDAC6 induces changes in the immune effector cells in MM microenvironment, and suggest novel immune-based epigenetic-targeted therapies.
Journal ArticleDOI
Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population
Jana Jakubikova,Teru Hideshima,Richard W.J. Groen,Danka Cholujova,Zdenka Bujnakova,Jacob P. Laubach,Nikhil C. Munshi,Paul G. Richardson,Constantine S. Mitsiades,Peter Balaz,Jan Sedlak,Kenneth C. Anderson +11 more
TL;DR: Overall, the results demonstrate significant anti-tumor activity of NREA against MM cells in vitro and in vivo data further show that N REA significantly decreased tumor burden at clinically achievable concentrations of arsenic.